TrialThe oncologist2022

A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide.

Keith T Schmidt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.